Mayukh Sukhatme Sells 284,707 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Key Points

• Insider selling: Mayukh Sukhatme sold 284,707 Roivant Sciences shares for approximately $10.3 million, reducing his position by 1.51% to 18.63 million shares. He also sold shares in two other recent transactions.
• Stock and financial performance: ROIV rose to $37.37, near its 52-week high of $37.46. The company beat quarterly EPS expectations but missed revenue estimates and remains unprofitable.
• Analyst outlook: Analysts maintain a “Moderate Buy” consensus, with a $35.14 average price target, although Citigroup raised its target to $46. Institutional investors own 64.76% of the company.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Mayukh Sukhatme sold 284,707 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the completion of the sale, the insider owned 18,630,739 shares in the company, valued at $675,364,288.75. This represents a 1.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total transaction of $8,810,302.71.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total transaction of $5,029,879.66.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock traded up $1.13 during trading hours on Tuesday, reaching $37.37. 6,409,504 shares of the company were exchanged, compared to its average volume of 5,396,372. Roivant Sciences Ltd. has a 1 year low of $11.54 and a 1 year high of $37.46. The stock's fifty day moving average is $34.16 and its 200 day moving average is $30.17. The firm has a market cap of $26.99 billion, a PE ratio of -70.51 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. The firm had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. Research analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Analysts Set New Price Targets

ROIV has been the topic of a number of recent analyst reports. Sanford C. Bernstein raised shares of Roivant Sciences to a "strong-buy" rating in a research report on Wednesday, July 29th. TD Cowen reissued a "buy" rating on shares of Roivant Sciences in a report on Thursday, August 6th. Bank of America reaffirmed a "neutral" rating on shares of Roivant Sciences in a report on Friday, July 31st. Citigroup increased their price objective on Roivant Sciences from $42.00 to $46.00 and gave the company a "buy" rating in a report on Monday, August 10th. Finally, Leerink Partners set a $42.00 target price on Roivant Sciences in a research note on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Roivant Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $35.14.

Institutional Trading of Roivant Sciences

Large investors have recently bought and sold shares of the business. SBI Securities Co. Ltd. grew its holdings in shares of Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company's stock worth $27,000 after buying an additional 1,166 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company's stock worth $27,000 after purchasing an additional 583 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of Roivant Sciences during the fourth quarter worth $47,000. Parallel Advisors LLC grew its position in Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock valued at $57,000 after buying an additional 520 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company's stock valued at $59,000 after buying an additional 2,665 shares during the period. Institutional investors and hedge funds own 64.76% of the company's stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source